Delaware | 26-1756290 | |||||
(State or Other Jurisdiction of Incorporation or Organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification Number) |
R. Erik Holmlin, Ph.D. President and Chief Executive Officer Bionano Genomics, Inc. 9540 Towne Centre Drive, Suite 100 San Diego, California 92121 (858) 888-7600 | Thomas A. Coll, Esq. Cooley LLP 10265 Science Center Drive San Diego, California 92121 (858) 550-6000 |
Large accelerated filer | ☐ | Accelerated filer | ☐ | ||||||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | ||||||
Emerging growth company |
Title of Each Class of Securities to be Registered(1) | | | Proposed Maximum Aggregate Offering Price(2) | | | Amount of Registration Fee(3) |
Common stock, par value $0.0001 per share | | | — | | | — |
Common stock, par value $0.0001 per share | | | — | | | — |
Debt Securities | | | — | | | — |
Warrants | | | — | | | — |
Total | | | $125,000,000 | | | $16,225 |
SEC registration fee | $ | 11,594 | |
FINRA filing fee | * | ||
Accounting fees and expenses | * | ||
Legal fees and expenses | * | ||
Transfer agent and registrar fees and expenses | * | ||
Trustee fees and expenses | * | ||
Printing and miscellaneous expenses | * | ||
Total | $ | 11,594 |
* | The amount of securities |
Exhibit Number | | ||
1.1* | Form of Underwriting Agreement. | ||
| |||
3.1+ | | ||
3.2 | |||
3.3+ | | ||
3.4 | |||
4.1 | | ||
| |||
| |||
Form of Warrant to Purchase Series D-1 Preferred Stock issued to | |||
| |||
4.5+ | | ||
4.6+ | | ||
4.7+ | | ||
4.8+ | | ||
4.9+ | | ||
| |||
Form of Warrant to Purchase Common Stock issued | |||
| |||
Specimen Preferred Stock Certificate and Form of Certificate of Designation of Preferred Stock. | |||
| |||
| Form of Debt Securities. | ||
| |||
| |||
| |||
| |||
| |||
| |||
| |||
25.1** | | Statement of Eligibility of Trustee under the Debt Indenture. | |
107+ |
* | To be filed by amendment or as an exhibit to a Current Report on Form 8-K and incorporated herein by reference, if applicable. |
** | To be filed in accordance with the |
+ | Previously filed with the |
(2) That, for the purpose of determining any liability |
By: | /s/ R. Erik Holmlin, Ph.D. | ||||||
R. Erik Holmlin, Ph.D. | |||||||
President and Chief Executive Officer |
Signature | Title | Date | ||
/s/ R. Erik Holmlin, Ph.D. | President, Chief Executive Officer and Director (Principal Executive Officer) | May 8, 2023 | ||
R. Erik Holmlin, Ph.D. | ||||
/s/ Christopher Stewart | Chief Financial Officer (Principal Financial and Accounting Officer) | May 8, 2023 | ||
Christopher Stewart | ||||
* | Director | May 8, 2023 | ||
David L. Barker, Ph.D. | ||||
* | Director | May 8, 2023 | ||
Yvonne Linney, Ph.D. | ||||
* | Director | May 8, 2023 | ||
Albert A. Luderer, Ph.D. | ||||
* | Director | May 8, 2023 | ||
Hannah Mamuszka | ||||
* | Director | May 8, 2023 | ||
Aleksandar Rajkovic, M.D., Ph.D. | ||||
* | Director | May 8, 2023 | ||
Christopher Twomey | ||||
* | Director | May 8, 2023 | ||
Kristiina Vuori, M.D., Ph.D. | ||||
* | Director | May 8, 2023 | ||
Vincent Wong, J.D., M.B.A. |
/s/ R. Erik Holmlin, Ph.D. | |||||||
R. Erik Holmlin, Ph.D. | |||||||
Attorney-in-fact | |||||||